Valproate-induced enuresis: A prospective study

dc.contributor.authorYamak, Wissam R.
dc.contributor.authorHmaimess, Ghassan
dc.contributor.authorMakke, Yamane
dc.contributor.authorSabbagh, Sandra El
dc.contributor.authorArabi, Maher R.
dc.contributor.authorBeydoun, Ahmad A.
dc.contributor.authorNasreddine, Wassim M.
dc.contributor.departmentNeurology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:07:29Z
dc.date.available2025-01-24T12:07:29Z
dc.date.issued2015
dc.description.abstractAim: The aim of this study was to determine the frequency and characteristics of secondary enuresis in children initiated on valproate treatment. Method: This was a prospective study conducted in children aged 5 to 12 years with suspected newly diagnosed epilepsy and maintained on valproate for at least 1 month. Adverse events spontaneously reported by parents were recorded at each follow-up visit. In addition, we specifically asked about enuresis and other side effects known to occur with valproate treatment. We assessed the frequency of enuresis and its association with a number of variables. Results: Seventy-two children (43 males and 29 females) with a mean age of 8 years 7 months (range 5-12y) were included in this study. Secondary enuresis developed in 17 (24%) of these children after, on average, 19.8 days of exposure to valproate. The data obtained from a multivariate analysis indicate that age was the only significant factor in predicting the development of enuresis. Enuresis ceased in all children after discontinuation of valproate use, and in 10 out of 11 children still on the drug. Interpretation: Secondary enuresis is a common adverse event associated with valproate use in children, which is not usually spontaneously reported and is reversible in most cases. © 2015 Mac Keith Press.
dc.identifier.doihttps://doi.org/10.1111/dmcn.12737
dc.identifier.eid2-s2.0-84935414207
dc.identifier.pmid25808512
dc.identifier.urihttp://hdl.handle.net/10938/31526
dc.language.isoen
dc.relation.ispartofDevelopmental Medicine and Child Neurology
dc.sourceScopus
dc.subjectAge factors
dc.subjectAnticonvulsants
dc.subjectChild
dc.subjectChild, preschool
dc.subjectEnuresis
dc.subjectEpilepsy
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectProspective studies
dc.subjectValproic acid
dc.subjectAnticonvulsive agent
dc.subjectCarbamazepine
dc.subjectAdolescent
dc.subjectAdverse drug reaction
dc.subjectAge
dc.subjectAlopecia
dc.subjectAnorexia
dc.subjectArticle
dc.subjectAtaxia
dc.subjectDizziness
dc.subjectDrowsiness
dc.subjectDrug induced headache
dc.subjectDrug substitution
dc.subjectDrug use
dc.subjectDrug withdrawal
dc.subjectFollow up
dc.subjectGastrointestinal symptom
dc.subjectGeneralized epilepsy
dc.subjectHair loss
dc.subjectHuman
dc.subjectIncreased appetite
dc.subjectMajor clinical study
dc.subjectMultivariate analysis
dc.subjectNausea
dc.subjectNocturnal enuresis
dc.subjectPreschool child
dc.subjectPriority journal
dc.subjectProspective study
dc.subjectRisk factor
dc.subjectVomiting
dc.subjectChemically induced
dc.titleValproate-induced enuresis: A prospective study
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2015-10059.pdf
Size:
124.54 KB
Format:
Adobe Portable Document Format

Collections